Eli Lilly Announces Manufacturing Facility in Houston

Eli Lilly and Company has announced plans to build a next-generation manufacturing facility at Generation Park in Houston, Texas. The new site—one of four U.S. facilities Lilly will announce this year—will produce active pharmaceutical ingredients (APIs) for the company’s expanding pipeline of small molecule medicines in cardiometabolic health, oncology, immunology, and neuroscience.

Expected to be operational within five years, the facility will create 615 high-wage jobs in engineering, science, and operations, along with 4,000 construction jobs during development. It will also be among the sites manufacturing orforglipron, Lilly’s first oral small-molecule GLP-1 receptor agonist, which is slated for regulatory submission for obesity treatment later this year.

Learn more